The Value of 3D Printing for Product & Clinical Development: 4C Medical’s Perspective

Mitral regurgitation is a disease in which the mitral valve is no longer performing optimally, causing blood leakage into the left atrium. A prevailing issue with current MR patients is that many are not eligible for surgery and therefore do not have any treatment options available. 4C Medical Technologies is developing a minimally invasive technology that addresses mitral regurgitation, and that could be an option for these patients. The company’s AltaValve has won multiple awards for its innovative design. The easy-to-use solution involves the insertion of a flexible implant into the left atrium through a catheter. The supra-annular positioning and atrial-only fixation minimize the risks of blood flow obstruction to the aorta and limit interaction with the left ventricle. This decreases the risks of complications for the patient.

As a startup, 4C Medical Technologies is facing a long road in putting their device on the market. In our webinar, Dr. Kumar outlines that a great idea alone isn’t enough. Understanding the anatomy of patients and the dynamic nature of structures, knowing the sizes of the device to select for the target population. All these issues and more, need to be confidently explained to investors and regulatory bodies. Materialise supported 4C Medical in bringing their concept to patient care. Take advantage of this webinar to learn about the development process and how to approach future plans.

What you will learn

  • What the key elements for a successful startup in the medical field are
  • At which stages of the medical device design live cycle accurate 3D models and 3D Printing add value
  • How 4C’s collaboration with Materialise supported them throughout the process and helped save time


Share on:

Share on Facebook
Share on Twitter
Share on LinkedIn
Share with Pocket


You might also like

More inspiration